MEI Pharma is focused on the clinical development of novel therapies for the treatment of cancer. We were incorporated in Delaware in December 2000 and began trading on Nasdaq in December 2003. Dr. Daniel Gold was appointed President & CEO in April 2010 and we established our headquarters in San Diego shortly thereafter. In December 2012, we completed a $27.5 million private placement in a financing led by new investors Vivo Ventures and New Leaf Venture Partners, followed by a $15.2 million registered offering in April 2013. Our common stock is traded on the Nasdaq Capital Market under the symbol MEIP.

financial information

Click here for our most recent filings with the U.S. Securities and Exchange Commission.

IRS Form 8937 - Rights Offering

IRS Form 8937 - Reverse Split

corporate governance

Code of Business Conduct and Ethics

[ View PDF ]

Audit Committee Charter

[ View PDF ]

Compensation Committee Charter

[ View PDF ]

Nominating & Governance Committee Charter

[ View PDF ]

annual report

Click here for our 2012 Annual Report

analyst coverage

Cowen and Company

Nicholas Bishop, Ph.D.
(646) 562-1378

Roth Capital Partners

Joseph Pantginis, Ph.D.
(646) 358-1907

Brian Klein, MD
(212) 271-3807

Please note that any opinions, estimates or forecasts made by analysts are theirs alone and do not represent those of MEI Pharma or its management. MEI Pharma does not by reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

stock info

Click here for our current stock quote.

events & webcasts

September 27, 2013 
BioCentury's NewsMakers in the Biotech Industry Conference
[ webcast + slides ]

September 11, 2013 
Stifel Healthcare Conference 
[ webcast + slides ]

August 13, 2013 
Wedbush Life Sciences Management Access Conference
[ webcast + slides ]


Pete De Spain

Vice President, Investor Relations
& Corporate Communications
MEI Pharma, Inc.
(858) 369-7199


Subscribe to news alerts by email

Enter the characters shown in the image.